Press release
Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and
About this update from Verastem, Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nVerastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT.\n\n\nA live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.\n\n\nAbout Verastem Oncology:\n\n\nVerastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.\n\n\nOur first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).\n\n\nFor more information, please visit www.verastem.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200528005057/en/\n\nVerastem Oncology:\n\nInvestors:\nJohn Doyle\nVice President, Investor Relations & Finance\n+1 781-469-1546\[email protected]\n\nJoseph Rayne\nArgot Partners\n+1 212 600 1902\[email protected]\n\nMedia:\nLisa Buffington\nCorporate Communications\n+1 781-292-4205\[email protected]\n\nSource: Verastem, Inc.","length":3259,"tagName":"div"}]